Décio dos Santos Pinto

Décio dos Santos Pinto

Auto-generated profile, based on publicly available information

Décio dos Santos Pinto

Department of Stomatology, University of São Paulo, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1998 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
VPV Patel
V Patel
ASA M Senderowicz
A M Senderowicz
DPD Pinto
D Pinto
TIT Igishi
T Igishi
MRM Raffeld
M Raffeld
JGJ.Silvio Gutkind
J.Silvio Gutkind
Flavopiridol (HMR 1275) has been identified recently as a novel antineoplastic agent in the primary screen conducted by the Developmental Therapeutics Program, National Cancer Institute. Flavopiridol inhibits most cyclin-dependent kinases (cdks) and displays unique anticancer properties. Here, we investigated whether this compound was effective against head and neck squamous cell carcinomas (HNSCC). Exposure of HNSCC cells to flavopiridol diminished cdc2 and cdk2 activity and potently inhibited cell proliferation (IC50 43-83 nM), which was concomitant with the appearance of cells with a sub-G1 DNA content. Moreover, DNA fragmentation and TUNEL (terminal deoxynucleotidyl transferase-mediated nick end labeling) reaction confirmed that flavopiridol induces apoptosis in all cell lines, even on certain HNSCC cells that are insensitive to apoptosis to DNA-damaging agents (gamma-irradiation and bleomycin). A tumorigenic HNSCC cell line was used to assess the effect of flavopiridol in vivo. Treatment (5 mg/kg per day, intraperitoneally) for 5 d led to the appearance of apoptotic cells in the tumor xenografts and caused a 60-70% reduction in tumor size, which was sustained over a period of 10 wk. Flavopiridol treatment also resulted in a remarkable reduction of cyclin D1 expression in HNSCC cells and tumor xenografts. Our data indicate that flavopiridol exerts antitumor activity in HNSCC, and thus it can be considered a suitable candidate drug for testing in the treatment of refractory carcinomas of the head and neck.

1 September 2006 in Neoplasia
Verified
Journal Article
Open access
CSCristiane H Squarize
Cristiane H Squarize
RCRogerio Castilho
Rogerio Castilho
VSVirote Sriuranpong
Virote Sriuranpong
DPDecio S. Pinto
Decio S. Pinto
JGJ.Silvio Gutkind
J.Silvio Gutkind
The development of head and neck squamous cell carcinoma (HNSCC) involves the accumulation of genetic and epigenetic alterations in tumor-suppressor proteins, together with the persistent activation of growth-promoting signaling pathways. The activation of epidermal growth factor receptor (EGFR) is a frequent event in HNSCC. However, EGFR-independent mechanisms also contribute to the activation of key intracellular signaling routes, including signal transducer and activator of transcription-3 (STAT3), nuclear factor kappaB (NFkappaB), and Akt. Indeed, the autocrine activation of the gp130 cytokine receptor in HNSCC cells by tumor-released cytokines, such as IL-6, can result in the EGFR-independent activation of STAT3. In this study, we explored the nature of the molecular mechanism underlying enhanced IL-6 secretion in HNSCC cells. We found that HNSCC cells display an increased activity of the IL-6 promoter, which is dependent on the presence of an intact NFkappaB site. Furthermore, NFkappaB inhibition downregulated IL-6 gene and protein expression, and decreased the release of multiple cytokines. Interestingly, interfering with NFkappaB function also prevented the autocrine/paracrine activation of STAT3 in HNSCC cells. These findings demonstrate a cross-talk between the NFkappaB and the STAT3 signaling systems, and support the emerging notion that HNSCC results from the aberrant activity of a signaling network.

20 March 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FGFernanda S. Giudice
Fernanda S. Giudice
DPDecio S. Pinto
Decio S. Pinto
JNJacques E. Nör
Jacques E. Nör
CSCristiane H Squarize
Cristiane H Squarize
RCRogerio Castilho
Rogerio Castilho
The genome is organized and packed into the nucleus through interactions with core histone proteins. Emerging evidence suggests that tumors are highly responsive to epigenetic alterations that induce chromatin-based events and dynamically influence tumor behavior. We examined chromatin organization in head and neck squamous cell carcinoma (HNSCC) using acetylation levels of histone 3 as a marker of chromatin compaction. Compared to control oral keratinocytes, we found that HNSCC cells are hypoacetylated and that microenvironmental cues (e.g., microvasculature endothelial cells) induce tumor acetylation. Furthermore, we found that chemical inhibition of histone deacetylases (HDAC) reduces the number of cancer stem cells (CSC) and inhibits clonogenic sphere formation. Paradoxically, inhibition of HDAC also induced epithelial-mesenchymal transition (EMT) in HNSCC cells, accumulation of BMI-1, an oncogene associated with tumor aggressiveness, and expression of the vimentin mesenchymal marker. Importantly, we observed co-expression of vimentin and acetylated histone 3 at the invasion front of human HNSCC tumor tissues. Collectively, these findings suggest that environmental cues, such as endothelial cell-secreted factors, modulate tumor plasticity by limiting the population of CSC and inducing EMT. Therefore, inhibition of HDAC may constitute a novel strategy to disrupt the population of CSC in head and neck tumors to create a homogeneous population of cancer cells with biologically defined signatures and predictable behavior.

2 April 2013 in Journal of Biophotonics
Verified
Journal Article
Closed access
PDF file
FSFelipe F. Sperandio
Felipe F. Sperandio
FGFernanda S. Giudice
Fernanda S. Giudice
LCLuciana Corrêa
Luciana Corrêa
DPDécio S. Pinto
Décio S. Pinto
Michael R. HamblinMichael R. Hamblin
Michael R. Hamblin
SSSuzana C.O.M. de Sousa
Suzana C.O.M. de Sousa

1 December 2010 in Oral Oncology
Verified
Journal Article
Closed access
AAAline Correa Abrahao
Aline Correa Abrahao
RCRogerio Castilho
Rogerio Castilho
CSCristiane H Squarize
Cristiane H Squarize
AMAlfredo A. Molinolo
Alfredo A. Molinolo
DSDecio dos Santos-Pinto
Decio dos Santos-Pinto
JGJ.Silvio Gutkind
J.Silvio Gutkind

15 July 2011 in Lasers in Medical Science
Verified
Journal Article
Closed access
PDF file
TSThais Oricchio Fedri de Souza
Thais Oricchio Fedri de Souza
DMDayane Aparecida Mesquita
Dayane Aparecida Mesquita
RMRaquel Agnelli Mesquita-Ferrari
Raquel Agnelli Mesquita-Ferrari
DPDécio dos Santos Pinto
Décio dos Santos Pinto
LCLuciana Corrêa
Luciana Corrêa
MMManoela Domingues Martins
Manoela Domingues Martins